Accumulate rating on Natco, target price of Rs 940: Nirmal Bang

Mylan, distribution partner for Natco Pharma in the US market, gets US Food and Drug Administration (US FDA) nod for generic version of Copaxone 20 mg tablet and 40 mg tablet.

Big opportunity for Natco Pharma, as they have got the approval before competitors, said Vishal Manchanda of Nirmal Bang Institutional Equities.

"Copaxone 20 mg launch maybe imminent but the 40 mg launch is subject to litigation outcome. So what Mylan can do is they can choose to launch at risk. If they choose to launch at risk, we see this as USD 200-300 million opportunities for them assuming no additional competitors enter by then," he added.

We have an accumulate rating on Natco with a price target of Rs 940 per share, said Manchanda.

Watch accompanying video for more details.